Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: A clinicopathologic study

Journal of Clinical Oncology

Volumn 24, Issue 28, 2006, Pages 4626-4633

  Asano, Naoko ^a   Oshiro, Aya ^b   Matsuo, Keitaro ^b   Kagami, Yoshitoyo ^b   Ishida, Fumihiro ^b   Suzuki, Ritsuro ^b   Kinoshita, Tomohiro ^b   Shimoyama, Yoshie ^b   Tamaru, Jun Ichi ^b   Yoshino, Tadashi ^b   Kitamura, Kunio ^b   Fukutani, Hisashi ^b   Morishima, Yasuo ^b   Nakamura, Shigeo ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD20 ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD79A ANTIGEN; CD8 ANTIGEN; CELL MARKER; COMPLEMENT COMPONENT C3D RECEPTOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANZYME B; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER RISK; CANCER SURVIVAL; CELL STRUCTURE; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; CLINICAL STUDY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; ADOLESCENT; BLOOD; CHILD; CYTOTOXIC T LYMPHOCYTE; HODGKIN DISEASE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PHENOTYPE; PRESCHOOL CHILD; T LYMPHOCYTE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 33750598940     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.5342     Document Type: Article

References (31)

1. Tzankov A, Zimpfer A, Pehrs AC, et al: Expression of B-cell markers in classical Hodgkin lymphoma: A tissue microarray analysis of 330 cases. Mod Pathol 16:1141-1147, 2003
2. Wang J, Taylor CR: Apoptosis and cell cycle related gene and proteins in classical Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 11:206-213, 2003
3. Kuppers R, Rajewsky K, Zhao M, et al: Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histologic sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 91:10962-10966, 1994
4. Cossman J, Annunziata CM, Barash S, et al: Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 94:411-416, 1999
5. Taylor CR, Riley CR: Evolving concepts of the nature of Hodgkin's disease: A history. Ann Diagn Pathol 4:337-346, 2000
6. Taylor CR, Riley CR: Molecular morphology of Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 9:187-202, 2001
7. Thomas RK, Re D, Wolf J, et al: Part I: Hodgkin's lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 5:11-18, 2004
8. Dallenbach FE, Stein H: Expression of T-cell-receptor beta chain in Reed-Sternberg cells. Lancet 2:828-830, 1989
9. Kadin ME, Muramoto L, Said J: Expression of T-cell antigens on Reed-Sternberg cells in a subset of patients with nodular sclerosing and mixed cellularity Hodgkin's disease. Am J Pathol 130:345-353, 1988
10. Seitz V, Hummel M, Marafioti T, et al: Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 95:3020-3024, 2000
11. Muschen M, Rajewsky K, Brauninger A, et al: Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med 191:387-394, 2000
12. Nakamura S, Nagahama M, Kagami Y, et al: Hodgkin's disease expressing follicular dendritic cell marker CD21 without any other B-cell marker. Am J Surg Pathol 23:363-376, 1999
13. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
14. Stein H, Delsol G, Pileri S, et al: Classical Hodgkin lymphoma, in Jaffe ES (ed): Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours. Lyons, France, OARC Press, 2001, pp 244-253
15. Asano N, Suzuki R, Kagami Y, et al: Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 29:1284-1293, 2005
16. MacLennan KA, Bennett MH, Tu A, et al: Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. Cancer 64:1686-1693, 1989
17. Tzankov A, Bourgau C, Kaiser A, et al: Rare expression of T-cell markers in classical Hodgkin's lymphoma. Mod Pathol 18:1542-1549, 2005
18. Krenacs L, Wellmann A, Sorbara L, et al: Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: Evidence for distinct cellular origin. Blood 89:980-989, 1997
19. Oudejans JJ, Kummer JA, Jiwa M, et al: Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 148:233-240, 1996
20. Gandhi MK: Epstein-Barr virus-associated Hodgkin's lymphoma. Br J Haematol 125:267-281, 2004
21. Clarke CA, Glaser SL, Dorfman RF, et al: Epstein-Barr virus and survival after Hodgkin disease in a population-based series of women. Cancer 91:1579-1587, 2001
22. Stark GL, Wood KM, Jack F, et al: Hodgkin's disease in the elderly: A population-based study. Br J Haematol 119:432-440, 2002
23. Jarrett RF, Stark GL, White J, et al: Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classical Hodgkin lymphoma: A population-based study. Blood 106:2444-2451, 2005
24. Enblad G, Sandvej K, Sundstrom C, et al: Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population. Acta Oncol 38:425-429, 1999
25. Glavina-Durdov M, Jakic-Razumovic J, Capkun V, et al: Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease. Br J Cancer 84:1227-1234, 2001
26. Flavell KJ, Killingham LJ, Biddulph JP, et al: The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease. Ann Oncol 14:282-290, 2003
27. Wasielewski R, Mengel M, Fischer R, et al: Classical Hodgkin's disease clinical impact of the immunophenotype. Am J Pathol 151:1123-1130, 1997
28. Ogawa S, Yamaguchi M, Oka K, et al: CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival. Br J Haematol 125:180-186, 2004
29. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
30. Bierman PJ, Lynch JC, Bociek RG, et al: The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 13:1370-1377, 2002
31. Pileri SA, Ascani S, Leoncini L, et al: Hodgkin's lymphoma: The pathologist's viewpoint. J Clin Pathol 55:162-176, 2002